L3VLUP
ProSign in

COO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterCOOJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 2023none listed holders, n.a.38 holders, $25.0bn
Q3 2023none listed holders, n.a.37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 202421 holders, $3.0bn32 holders, $19.7bn
Q2 202419 holders, $2.5bn35 holders, $20.4bn
Q3 202419 holders, $3.3bn28 holders, $22.3bn
Q4 202416 holders, $2.9bn37 holders, $20.4bn
Q1 202519 holders, $3.2bn32 holders, $20.5bn
Q2 202521 holders, $3.0bn31 holders, $18.4bn
Q3 202516 holders, $3.2bn32 holders, $23.7bn
Q4 202517 holders, $3.4bn29 holders, $27.8bn
Q1 202613 holders, $2.6bn34 holders, $35.6bn
Q2 202619 holders, $2.6bn33 holders, $39.1bn
COO

Cooper Cos Inc

Holders
17
Reported value
$3.4bn
Buyers
13
Sellers
20

Breadth -7 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COO (6)

Balyasny Asset Management LLC, ExodusPoint Capital Management LP, Jana Partners, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Winton Group Ltd

Only JNJ (18)

Acadian Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →